Plasma total homocysteine levels in children with type 1 diabetes: Relationship with vitamin status, methylene tetrahydrofolate reductase genotype, disease parameters and coronary risk factors

Journal of Tropical Pediatrics

Volumn 52, Issue 4, 2006, Pages 260-266

  Dinleyici, E C ^a   Kirel, Birgul ^a   Alatas, Ozkan ^a   Muslumanoglu, Hamza ^a   Kilic, Zubeyir ^a   Dogruel, Nesrin ^a  

^a ESKISEHIR OSMANGAZI UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; TRIACYLGLYCEROL;

AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CHILD; CHILD NUTRITION; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORONARY RISK; CORRELATION ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; ENZYME POLYMORPHISM; FEMALE; FOLIC ACID BLOOD LEVEL; GENOTYPE; GLOMERULUS FILTRATION RATE; HEREDITY; HUMAN; HYPERHOMOCYSTEINEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLIC REGULATION; ONSET AGE; PREVALENCE; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL;

ADOLESCENT; CHILD; CORONARY DISEASE; DIABETES MELLITUS, TYPE 1; FEMALE; HOMOCYSTEINE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); RISK FACTORS; VITAMINS;

EID: 33748120033     PISSN: 01426338     EISSN: 14653664     Source Type: Journal    
DOI: 10.1093/tropej/fmk001     Document Type: Article

References (44)

1. Grundy SM, Howard B, Smith S Jr, et al. Prevention Conference VII: Diabetes and Cardiovascular Disease: Executive summary: conference proceeding for health care professionals from a special writing group of the American Heart Association. Circulation 2002;105: 2231-9.
2. Krantz JS, Mack WJ, Hodis HN, et al. Early onset of subclinical atherosclerosis in young persons with type 1 diabetes. J Pediatr 2004;145:452-7.
3. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274: 1049-57.
4. Pavia C, Ferrer I, Valls C, et al. Total homocysteine in patients with type 1 diabetes. Diabetes Care 2000; 23:84-7.
5. Wiltshire E, Thomas DW, Baghurst P, Couper J. Reduced total plasma homocyst(e)ine in children and adolescents with type 1 diabetes. J Pediatr 2001; 138:888-93.
6. Cotellessa M, Minniti G, Cerone R, et al. Low total plasma homocysteine concentrations in patients with type 1 diabetes. Diabetes Care 2001;24:969-71.
7. Robillon JF, Canivet B, Candito M, et al. Type 1 diabetes mellitus and homocyst(e)ine. Diabete Metab 1994;20:494-6.
8. Cronin CC, McPartlin JM, Barry DG, et al. Plasma homocysteine concentrations in patients with type 1 diabetes. Diabetes Care 1998;21:1843-7.
9. Agullo-Ortuno MT, Albaladejo MD, Parra S, et al. Plasmatic homocysteine concentration and its relationship with complications associated to diabetes mellitus. Clin Chim Acta 2002;326:105-12.
10. Glowinska B, Urban M, Koput A, Galar M. New atherosclerosis risk factors in obese, hypertensive, and diabetic children and adolescents. Atherosclerosis 2003;167:275-86.
11. Chico A, Perez A, Cordoba A, et al. Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus: A new link between diabetic nephropathy and cardiovascular disease? Diabetologia 1998;41:684-93.
12. Hofman MA, Kohl B, Zumbach MS, et al. Hyperhomocyst(e)nemia and endothelial dysfunction in IDDM. Diabetes Care 1998;21:841-8.
13. Okada E, Oida K, Tada H, et al. Hyperhomocysteinemia is a risk factor for coronary arteriosclerosis in Japanese patients with type 2 diabetes. Diabetes Care 1999;22:484-90.
14. Shcherbak NS, Shutskaya ZV, Sheidina AM, et al. Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy in IDDM patients. Mol Genet Metab 1999;68:375-8.
15. Vaccaro O, Perna AF, Mancini FP, et al. Plasma homocysteine and microvascular complications in type 1 diabetes. Nutr Metab Cardiovasc Dis 2000;10: 297-304.
16. Araki A, Sako Y, Ito H. Plasma homocysteine concentrations in Japanese patients with non-insulin dependent diabetes mellitus: Effect of parental methylcobalamin treatment. Atherosclerosis 1993;103: 149-57.
17. Agardh CD, Agardh E, Andersson A, Hultberg B. Lack of association between plasma homocysteine levels and microangiopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 1994;54:637-41.
18. Hultberg B, Agardh E, Andersson A, et al. Increased levels of plasma homocysteine are associated with nephropathy, but not severe retinopathy in type 1 diabetes mellitus. Scand J Clin Lab Invest 1991;51: 277-82.
19. De Bree A, Verschuren WM, Kromhout D, et al. Homocysteine determinants and the evidence to what extent homocysteine determines the risk of coronary heart disease. Pharmacol Rev 2002;54:599-618.
20. Fonseca V, Guba SC, Fink LM. Hyperhomocysteinemia and the endocrine system: Implications of atherosclerosis and thrombosis. Endocr Rev. 1999; 20:738-59.
21. Frosst P, Blom HJ, Milos R, et al. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995;10:11-113.
22. Jacques PF, Bostom AG, Williams RR, et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996;93:7-9.
23. van der Putt NM, Gabreels F, Stevens EM, et al. A second common mutation in the methylenetetrahydrofolate reductase gene: An additional risk factor for neural-tube defects? Am J Hum Genet 1998;62: 1044-51.
24. Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. Annu Rev Nutr 1992;12:279-98.
25. Diabetic nephropathy. Diabetes Care 2002; 25(Suppl 1):S85-9.
26. Counahan R, Chantler C, Ghazali S, et al. Estimation of glomerular filtration rate from plasma creatinine concentration rate. Arch Dis Child 1976;51:875-8.
27. Greenlund KJ, Srinivasan SR, Xu JH, et al. Plasma homocysteine distribution and its association with parental history of coronary artery disease in black and white children: The Bogalusa Heart Study. Circulation 1999;99:2144-9.
28. Delvin EE, Rozen R, Merouani A, et al. Influence of methylenetetrahydrofolate reductase genotype, age, vitamin B12, and folate status on plasma homocysteine in children. Am J Clin Nutr 2000; 72:1469-73.
29. Kaye JM, Stanton KG, McCann VJ, et al. Homocysteine, folate, methylene tetrahydrofolate reductase genotype and vascular morbidity in diabetic subjects. Clin Sci (Lond) 2002;102:631-7.
30. Selhub J, Jacques PF, Wilson PW, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993; 270:2693-8.
31. Tokgozoglu SL, Alikasifoglu M, Unsal I, et al. Methylene tetrahydrofolate reductase genotype and the risk and extent of coronary artery disease in a population with low plasma folate. Heart 1999;81: 518-22.
32. Shpichinetsky V, Raz I, Friedlander Y, et al. The association between two common mutations C677T and A1298C in human methylenetetrahydrofolate reductase gene and the risk for diabetic nephropathy in type II diabetic patients. J Nutr 2000;130: 2493-7.
33. Brzosko S, Mysliwiec M, Donati MB, Iacoviello L. Hyperhomocysteinemia in patients with type 1 diabetes in relation to renal function. Diabetes Care 2001;24: 2158.
34. Wollesen F, Brattstrom L, Refsum H, et al. Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 1999;55:1028-35.
35. Neugebauer S, Baba T, Watanabe T. Methylenetetrahydrofolate reductase gene polymorphism as a risk factor for diabetic nephropathy in NIDDM patients. Lancet 1998;352:454.
36. Hultberg B, Agardh CD, Agardh E, Lovestam-Adrian M. Poor metabolic control, early age at onset, and marginal folate deficiency are associated with increasing levels of plasma homocysteine in insulin-dependent diabetes mellitus. A five year follow-up study. Scand J Clin Lab Invest 1997;57:595-600.
37. Alsaeid M, Qabazard M, Shaltout A, Sharma PN. Impact of glycemic control on serum lipoprotein (a) in Arab children with type 1 diabetes. Pediatr Int 2001;43:246-50.
38. Passaro A, D'Elia K, Pareschi PL, et al. Factors influencing plasma homocysteine levels in type 2 diabetes. Diabetes Care 2000;23:420-21.
39. Garg A. Management of dyslipidemia in IDDM patients. Diabetes Care 1994;17:224-34.
40. Martinez MT, Perez F, Calvillan M, et al. Lipoprotein (a) and other risk factors in Chilean children with type 1 diabetes. Rev Med Chil 1994; 122:1115-9.
41. Jenkins AJ, Lyons TJ, Zheng D, et al. Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort, associations with gender and glycemia. Diabetes Care 2003;26:810-18.
42. Glowinska B, Urban M, Peczynska J, et al. Elevated concentrations of homocysteine in children and adolescents with artereial hypertension accompanying type 1 diabetes. Med Sci Monit 2001;7:1242-9.
43. Elgharib N, Chi DS, Younis W, et al. C-reactive protein as a novel biomarker. Reactant can flag atherosclerosis and help predict cardiac events. Postgrad Med 2003; 114:39-44.
44. Kilpatrick ES, Keevil BG, Jagger C, et al. Determinants of raised c-reactive protein concentration in type 1 diabetes. Quart J Med 2000;93:231-6.